Director sold ~$527K of Exelixis
Scheduled in advanceLoading…
Exelixis
EXEL · NASDAQ · Biotechnology
EXEL · NASDAQ · Biotechnology
Biotechnology company based in Alameda, California.
In the last 90 days, no insider of Exelixis reported an open-market purchase and 1 open-market sale worth about $527K. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$58.85
Last 12 months
Not enough history
Market value
$14.6B
Revenue
$629M
+10.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.17B
This quarter $301M, a year earlier $46.2M
Net debt
—
Debt —, cash $281M, at Jul 3, 2026
Net income, last 12 months
$861M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 5, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
1 sale
$527K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2026
$2.32B
+7.0% vs the year before
Net income, fiscal 2026
$783M
As reported in the annual filing
Shares outstanding
248M
As of Jul 27, 2026
In fiscal 2026 the company spent $948M buying back its own shares. Cash actually paid, from its cash-flow statement.
Director sold ~$527K of Exelixis
Scheduled in advanceDirector sold ~$492K of Exelixis
Scheduled in advanceDirector sold ~$198K of Exelixis
Scheduled in advanceOfficer sold ~$1.6M of Exelixis
Automatic salePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
10 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in colorectal cancer, differentiated thyroid cancer, hepatocellular carcinoma. The ones with the nearest registered primary completion date still ahead:
5 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last 12 months, adjusted daily closes
Adjusted close went from $40.01 on Oct 6, 2025 to $58.85 on Oct 5, 2026 (+47.1%). Disclosed activity in the last 12 months: 1 insider purchase, 32 insider sales (30 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.